Physician profile
Guido Barmaimon
NPI 1952748782
$1,297.43
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2021: $210 · 2022: $437 · 2023: $366 · 2024: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $387.16 | 2021-2024 | Nucala, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.52 | 2021-2024 | Ofev |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $112.82 | 2022-2023 | Lifevest |
| Genentech USA, INC. | $99.99 | 2019 | |
| United Therapeutics Corporation | $56.78 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $55.58 | 2022-2024 | Zerbaxa, Dificid, Recarbrio |
| Advanced Respiratory, INC | $54.76 | 2021 | |
| Grifols USA, LLC | $51.55 | 2022-2023 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $51.04 | 2022 | |
| Mindray Ds USA, INC. | $44.81 | 2024 | Te X, Te7 Max |
| Inari Medical, INC. | $31.58 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbvie INC. | $30.86 | 2022-2023 | Teflaro |
| Astrazeneca Pharmaceuticals LP | $30.86 | 2022-2024 | Tezspire |
| Paratek Pharmaceuticals, INC. | $29.79 | 2021 | |
| Medtronic, INC. | $26.19 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.62 | 2022 | |
| Philips North America LLC | $20.00 | 2023 | |
| Inquis Medical, INC. | $18.13 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.82 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.71 | 2021 | |
| Amgen INC. | $13.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guido Barmaimon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.